Skip to main content
Fig. 3 | Molecular Medicine

Fig. 3

From: Insulin-like Growth Factor I and Urokinase-type Plasminogen Activator Bioregulation System as a Survival Mechanism of Prostate Cancer Cells in Osteoblastic Metastases: Development of Anti-Survival Factor Therapy for Hormone-Refractory Prostate Cancer

Fig. 3

The novel concept of combination therapy.

Combination therapy employs the anti-survival factor (ASF) therapeutic approach and anti-cancer therapies, such as androgen ablation therapy or cytotoxic chemotherapy. IGF-1 = insulin-like growth factor-1.

Back to article page

Molecular Medicine

ISSN: 1528-3658